Marshall Wace, LLP Kiniksa Pharmaceuticals, Ltd. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$13.62 - $20.2 $2.28 Million - $3.38 Million	-167,312 Reduced 51.39%	158,230 $2.75 Million
Q2 2023 Aug 14, 2023	SELL	$10.44 - $16.48 $5.02 Million - $7.93 Million	-481,283 Reduced 59.65%	325,542 $4.58 Million
Q1 2023 May 15, 2023	BUY	$10.7 - $15.79 $7.05 Million - $10.4 Million	658,886 Added 445.38%	806,825 $8.68 Million
Q4 2022 Feb 14, 2023	BUY	$11.42 - $17.05 $1.69 Million - $2.52 Million	147,939 New	147,939 $2.22 Million
Q1 2022 May 16, 2022	SELL	$9.3 - $12.37 $648,423 - $862,473	-69,723 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$10.39 - $15.15 $724,421 - $1.06 Million	69,723 New	69,723 $821,000
Q1 2021 May 17, 2021	SELL	$16.68 - $23.97 $1.31 Million - $1.88 Million	-78,352 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$14.8 - $21.15 $1.04 Million - $1.48 Million	-69,951 Reduced 47.17%	78,352 $1.38 Million
Q3 2020 Nov 16, 2020	BUY	$15.21 - $25.53 $2.26 Million - $3.79 Million	148,303 New	148,303 $2.27 Million

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.